CSF1R and colitis: The molecular and cellular pharmacology and safety of JNJ-40346527 in a phase IIA study in rheumatoid arthritis were reported previously.[21] In the current work, we assessed the ability of JNJ-40346527 to suppress CSF-1R-driven biology in the murine T-cell transfer (TCT) model of colitis to determine whether it would impact inflammation and disease indices.